World Pharmaceutical Frontiers’ Post

Join me at the inaugural AACR Oncology Partnering Event next week on April 4-5 at the San Diego Convention Center. This event precedes the AACR Annual Meeting 2024, where our dedicated team from Domain Therapeutics, we will be presenting the transformative insights on DT-9045, our first-in-class Negative Allosteric Modulator of PAR2. This drug candidate, backed by our rigorous precision research, is a true game-changer in #immunooncology boasting unprecedented pharmacological properties. Additionally, our lead clinical candidate DT-9081, part of the EP4 program, has a unique strategic positioning and a significant potential to increase success rates in tumor types with solid rational involving prostaglandin-mediated immunoresistance. I’m also excited to share with you the latest developments on our pioneering preclinical drug candidate, Treg depletant anti-CCR8 DT-7012. This innovative compound demonstrates breakthrough properties and is rapidly evolving into a valuable asset that could revolutionize cancer treatment. We are determined to provide solutions to patients facing therapeutic failure in the clinic and defeat cancer. Every milestone we reach takes us another step closer to making a tangible difference in the lives of cancer patients worldwide. Big thanks to American Association for Cancer Research for your dedication to advancing #cancerresearch and for providing this platform to engage with industry leaders and share insights about the future of immuno-oncology. Reach out if you would like to connect in person or interested to learn more about our work. Follow Domain for more updates on our journey towards transforming cancer treatment. #drugdevelopment #immunotherapy

I am delighted to share the announcement of a #collaboration that I have initiated and will be leading on behalf of my client OregonTherapeutics trough my service Lab2BIOTECH. This collaboration involves the analysis of the #preclinical package of Oregon Therapeutics' lead product, XCE853, by Lantern Pharma Inc. (Nasdaq: LTRN) Pharma's #AI based RADR® platform, in order to identify the best clinical positioning of this #drug candidate for #Cancer patient's and further progress toward clinics together.  Please see the press release below. --- Personal notes: This is AI as I like it: no buzzwords, concrete analysis of huge datasets and literature points to leverage smarter strategies in #drugdevelopment and improve patient's impact. This collaboration is also a good illustration of my vision on how best to develop assets for startups. Licensing a drug candidate is not a final step at the end of a development plan. It's an ongoing process, starting from day one of project management, and requires open-mindedness, seeking out opportunities and collaborating with potential licensees to build trust and improve product-market fit with payers' expectations, while driving R&D forward.  Tip for founders: surround yourself!

What a day for biotech financings! CatalYm GmbH, one of four companies who raised a megaround today, snagged an $150-million series D to move its GDF-15 inhibitor visugromab into first-line lung cancer patients. The protein plays a key role in fetomaternal tolerance, but cancer can hijack that mechanism to avoid immune detection, CEO Phil L'Huillier told me. Targeting GSF-15 also has another benefit -- it can reduce the nausea and vomiting triggered by other cancer treatments. “When we neutralise GDF-15 to treat cancer, not only are we treating the cancer through the immune mechanism, but we’re also treating the sickness that’s often associated with chemotherapies, radiotherapies, and ADCs ,” L'Huillier explained. For more on CatalYm's clinical plans and the American Society of Clinical Oncology (ASCO) data that triggered Tuesday's round, read the story here: https://lnkd.in/gDcHZQUm

Cancer treatment is evolving, and at Immunai we're excited to play a key role in shaping its future. Immunai's new multi-year collaboration with AstraZeneca a aims to advance oncology clinical trials by leveraging our AI platforms, AMICA™, and the Immunodynamics Engine (IDE)™. We’re working together to gain deeper insights into patient responses, optimize dose selection, and identify key biomarkers for cancer treatment. Learn more about the collaboration from https://lnkd.in/dQNZ-u9e

Crossignal Therapeutics Inc Therapeutics has been recognized as one of the Top Immunotherapy Solutions Providers by Pharma Tech Outlook. Crossignal Therapeutics pioneers novel small molecule immunotherapies, targeting key receptors like GPCRs and the Hippo-YAP pathway. Their precision screening platform revolutionizes cancer treatment, advancing precision medicine affordable and effective cancer treatment. “We focus on the discovery of immune cell-expressed, tumor microenvironment factors (TME)-targeted GPCRs (TMERs) and design our drug candidates by testing their ability to inhibit critical pathways in TME-mediated cancer immune escape. We are driven by our deep-rooted experience in immunology & oncology, GPCR signal transduction, and drug discovery to develop a whole new generation of IO therapeutics,” says Zhi Liang Chu Ph.D. Founder, CEO & CSO The article will also be featured in the forthcoming special print edition on Immunotherapy Solutions company 2024. Read More:https://shorturl.at/jHVZ6 #immunotherapy #microenvironment #oncologyresearch #immuneattacks

AI-Driven Metabolic Insights: Transforming Cancer Drug Candidates into Prodrug Successes Cancer therapies are essential in saving lives but come with significant challenges. The average cost of developing a new cancer drug is a staggering $2.77 billion, with a timeline of 6-12 years. A major factor driving these costs is the “translational gap,” where preclinical results often fail to predict clinical outcomes, leading to high failure rates in trials. Join Margaret K Offermann from OncoSpherix and Jo Varshney from VeriSIM Life in our upcoming webinar to discover how we leveraged #hybridAI to overcome these challenges. We utilized AI-driven insights to uncover pharmacokinetic anomalies and metabolic influences, guiding our lead compound toward a more promising prodrug variant. Here is what you will be able to take away from this session: - Overcoming hurdles in first-in-class cancer drug development using hybridAI. - Understanding metabolic processes in a drug’s mechanism of action. - Business outcomes of using hybridAI to reveal metabolic interactions that enhance success rates.

Astellas Pharma US and Kelonia Therapeutics Team Up to Revolutionize CAR-T Therapy! Great news for cancer patients! Astellas Pharma and Kelonia Therapeutics have joined forces to develop next-generation CAR-T cell therapies using innovative technologies. What's the deal? Xyphos, a subsidiary of Astellas, will combine their ACCEL™ technology (improves CAR-T therapy control) with Kelonia's iGPS® system (delivers genes precisely within the body). This powerful combo aims to create in vivo CAR-T therapies, meaning the treatments happen inside the patient's body, potentially offering greater convenience and efficiency. The collaboration focuses on two cancer programs, with potential for expansion. Why is this exciting? CAR-T therapies have shown immense promise in treating cancer, but face challenges like complex manufacturing and limited control. This collaboration tackles these challenges, potentially leading to more effective and accessible CAR-T treatments. This advancement could benefit patients with various solid and blood cancers. What's next? The companies will work together to develop and commercialize these innovative therapies. This collaboration represents a significant step forward in revolutionizing CAR-T therapy and offering new hope for cancer patients. Stay tuned! This partnership holds immense potential for the future of cancer treatment. #cancerresearch #CAR-Ttherapy #innovation #collaboration #makingadifference

As we stand on the brink of the American Association for Cancer Research (AACR) Annual Meeting, we are eager to share our recent strides in DNA Damage Repair (DDR) Inhibitors with the worldwide scientific community.✨ Our dedicated team's work on DDR inhibitors, specifically Debio 0123 and Debio 0432, has furnished us with valuable insights into potential strategies for tackling hard-to-treat cancers. This unwavering commitment continues to propel these crucial advancements forward.   👋Don't hesitate to join us during our poster presentations throughout the congress. These sessions will offer a unique opportunity to delve deeper into our data and explore the promising potential of DDR inhibitors in transforming cancer treatment. Read the press release 👇 #AACR24 #Oncology #DrugDevelopment #PrecisionMedicine #DDRInhibitors

Elicera Therapeutics has achieved some great things recently and we have continued to develop and grow, establishing ourselves as leaders in the field of CAR T-cell therapy and oncolytic viruses Here are 5 of our recent highlights: 1️⃣ A successful share issue raised SEK 27.6 million, enabling the first clinical trial (CARMA) with our CAR T-cells (ELC-301) armed with the iTANK technology. 2️⃣ CARMA study launched which aims to evaluate ELC-301's safety and efficacy against B-cell malignancies, with plans to treat 18 patients and reach significant milestones in our development program. 3️⃣ Proceeds from the share issue also support the ongoing commercialization of iTANK and further development of our other programs. 4️⃣ We established a partnership with a leading US cancer center to explore expanding iTANK to T-cell receptor therapies (TCR-T). 5️⃣ Our co-founder, Professor Magnus Essand, secured SEK 4.8 million from the Swedish Childhood Cancer Fund to study CAR T-cells' efficacy against brain tumors in children. Explore our annual report: https://lnkd.in/gAw6gmNc Check out our quarterly report: https://lnkd.in/gxvsc3Pk #CARTCellTherapy #Biotech #CellTherapy

🔬"Let's Outdo Cancer" : Pfizer's Commitment 🔬 Pfizer is expanding its focus beyond the recent challenges posed by COVID, and are diving further into the world of oncology. The article published by Fierce Biotech provides a fantastic overview of Pfizer’s strategic initiatives to strengthen its cancer pipeline, with a particular emphasis on Antibody-Drug Conjugates (ADCs). Pfizer is positioning itself at the forefront of cancer research, demonstrating their commitment to ground-breaking solutions! Read the full article below! #pfizer #cancerresearch #innovation #adcs #oncology #news